RSV prevention in all infants: which is the most preferable strategy?
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and
young children that may lead to hospitalizations and a substantial number of outpatient …
young children that may lead to hospitalizations and a substantial number of outpatient …
COVID-19: Transmission, prevention, and potential therapeutic opportunities
M Lotfi, MR Hamblin, N Rezaei - Clinica chimica acta, 2020 - Elsevier
The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense …
syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense …
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
P Irrgang, J Gerling, K Kocher, D Lapuente… - Science …, 2022 - science.org
RNA vaccines are efficient preventive measures to combat the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic. High levels of neutralizing SARS-CoV-2 …
syndrome coronavirus 2 (SARS-CoV-2) pandemic. High levels of neutralizing SARS-CoV-2 …
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
AT Ruffin, H Li, L Vujanovic, DP Zandberg… - Nature Reviews …, 2023 - nature.com
Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …
[HTML][HTML] Deployment of convalescent plasma for the prevention and treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …
disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven …
An update on current therapeutic drugs treating COVID-19
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …
[HTML][HTML] Distinct early serological signatures track with SARS-CoV-2 survival
As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some
individuals recover from infection, whereas others rapidly progress and die. Although the …
individuals recover from infection, whereas others rapidly progress and die. Although the …
Potential therapeutic options for COVID-19: an update on current evidence
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …
pandemic and is a major public health concern nowadays. The rapid and global spread of …
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
AM Arvin, K Fink, MA Schmid, A Cathcart, R Spreafico… - Nature, 2020 - nature.com
Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …
development of vaccines and antibody therapies because the mechanisms that underlie …
Humoral responses and serological assays in SARS-CoV-2 infections
Y Galipeau, M Greig, G Liu, M Driedger… - Frontiers in …, 2020 - frontiersin.org
In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …